If you have been reading about storage stability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
intermediates in biosynthesis, in post-translational formation of proteins, in a physiological role (e.g. components of bacterial cell walls, neurotransmitters and toxins), natural or man-made pharmacological compounds, present in meteorites or used in prebiotic experiments (such as the Miller–Urey experiment), might be important neurotransmitters, such as γ-aminobutyric acid, and can play a crucial role in cellular bioenergetics, such as creatine.
In fluid dynamics, the Darcy–Weisbach equation is an empirical equation that relates the head loss, or pressure loss, due to viscous shear forces along a given length of pipe to the average velocity of the fluid flow for an incompressible fluid. The equation is named after Henry Darcy and Julius Weisbach. Currently, there is no formula more accurate or universally applicable than the Darcy–Weisbach supplemented by the Moody diagram or Colebrook equation. The Darcy–Weisbach equation contains a dimensionless friction factor, known as the Darcy friction factor. This is also variously called the Darcy–Weisbach friction factor, friction factor, resistance coefficient, or flow coefficient.
=== Paediatric modification of red blood cell concentrates === Red blood cell concentrates can be modified to be suitable for paediatric patients. These modifications include split of regular units into smaller units (usually 3 – 6 parts), which facilitates limiting the number of involved donors at repeated transfusions. The modification can also be red blood cells for intrauterine transfusion where, in short, the additive solution is removed, which increases the haematocrit to between 0.70 – 0.85. A red blood cell concentrate can also be tailored for exchange transfusions for neonates. During this process, the additive solution is removed and instead, plasma is added to resemble a "whole blood". Both at intrauterine and exchange transfusion, compatibility between the foetus/baby and the mother is of great importance.
== Causes == Hyperglycemia may be caused by: diabetes, various (non-diabetic) endocrine disorders (insulin resistance and thyroid, adrenal, pancreatic, and pituitary disorders), sepsis and certain infections, intracranial diseases (e.g. encephalitis, brain tumors (especially if near the pituitary gland), brain haemorrhages, and meningitis) (frequently overlooked), convulsions, end-stage terminal disease, prolonged/major surgeries, stress, and excessive eating of carbohydrates.
Sources: en.wikipedia.org
=== Neurocognitive safety === Studies of SSRIs in patients with major psychiatric disorders prove that SSRIs are potentially associated with certain neurocognitive adverse effects such as anxiety, akathisia, hypomania, changes in mood, or suicidal thought. No study on the effects of SSRIs in men with PE has been done. McMahon's study in 2012 showed that dapoxetine has no effect on mood and is not associated with anxiety or suicidality.
=== 1970 === January 15: The Nigerian Civil War ends with Biafra being re-integrated into Nigeria. March 5: Treaty on the Non-Proliferation of Nuclear Weapons, ratified by the United Kingdom, the Soviet Union and the United States, among others, enters into force. March 18: Lon Nol takes power in Cambodia and establishes the Khmer Republic. Khmer Rouge and Vietnamese Communists attack the new regime, which wants to end North Vietnamese presence in Cambodia. August 7: The War of Attrition ends with a ceasefire. August 12: The Soviet Union and West Germany sign the Treaty of Moscow. August 17: Venera 7 is launched. September 6: Black September begins in Jordan. October 24: Salvador Allende becomes president of Chile after being confirmed by the Chilean congress. November 18: United States' aid to Cambodia to support the Lon Nol regime begins. December 15: Venera 7 lands on Venus becoming the first spacecraft to softly land on another planet.
== Resurgence == By the late 2010s, many observers, including The New York Times, pointed to Detroit's economic and cultural resurgence. This resurgence was primarily due to private and public investment revitalizing the city's social and economic dynamics. Detroit has achieved a renewed sense of interest through reinvestment and revamped social policies. It serves as a model for other areas to learn how to re-energize their urban centers. In 2024, the United States Census Bureau reported that Detroit experienced a slight population increase in its 2023 estimates, marking the city's first recorded growth since 1957. Evidence of Detroit's resurgence is most readily found in the Midtown Area and the Central Business District, which have attracted a number of high-profile investors. Most notably, Dan Gilbert has heavily invested in the acquisition and revitalization of a number of historic buildings in the Downtown area. A primary focus of private real estate investment has been to position Detroit's Central Business District as an attractive site for the investment of technology companies such as Amazon, Google, and Microsoft. Approaches to the private investment of Midtown, however, have prioritized re-establishing Midtown as the cultural and commercial center of the city. Midtown Cultural Connection's DIA Plaza Project, for instance, aims to unify the city's cultural district—which includes the Detroit Institute of Arts, Detroit Public Library, the Charles H.
Sources: en.wikipedia.org
Unlike other DOx drugs like DOM, DOPR, DOBU, and DOAM, 2,5-DMA does not produce hyperlocomotion in rodents and instead dose-dependently produces only hypolocomotion. On the other hand, it does similarly produce hypothermia at higher doses. Though 2,5-DMA appears to be inactive or of very low potency as a psychedelic in humans, it is a highly potent anti-inflammatory drug similarly to other DOx and 2C drugs. This was in spite of it being of very low potency as a serotonin 5-HT2A receptor agonist in terms of calcium mobilization in the study (EC50 = 3,548 nM; Emax = 109.0%). Based on the preceding findings, Charles D. Nichols has said that both fully anti-inflammatory non-psychedelic compounds like 2,5-DMA and fully psychedelic non-anti-inflammatory compounds like DOTFM are known.
=== Protists === Brine pockets harbor a diverse and abundant array of protists that are able to survive in extreme conditions. The most common protists in sea ice are pennate diatoms, which can accumulate in numbers so high that sea ice is visibly discolored brown. Sea ice pennate diatom populations can become very dense, reaching up to 1000 μg of chlorophyll per liter of seawater, compared to a typical maximum of 5 μg/L in the open ocean. Due to their high abundance in sea ice, pennate diatoms can profoundly impact the microecosystem within a brine pocket, such as DMSP production. Although diatoms themselves are not high producers of DMSP overall, because of their high abundance within sea ice, the amount of DMSP produced within sea ice as a cryoprotectant and osmoregulator can be impactful. In addition to pennate diatoms, brine pockets and channels house a variety of flagellates, amoebae, and ciliates. Protist abundance and diversity within a brine pocket/channel is primarily limited to brine pocket/channel structure. Specifically, the size of pores and channels within the ice can limit or encourage the distribution of certain protists and metazoans, with some areas with larger pore sizes having greater abundances of large predatory protists such as ciliates, and other areas with reduced populations of predatory protists due to smaller pore sizes.
Microfluidics is widely used for biochemical experiments, so it is important that surfactants are biocompatible when working with living cells and high-throughput analysis. Surfactants used in living cell research devices should not interfere with biochemical reactions or cellular functions. Hydrocarbon oil is typically not used in cell microfluidic research because it is not compatible with cells and damages cell viability. Hydrocarbon oil also extracts organic molecules from the aqueous phase. However, fluorosurfactants with fluorinated tails, for example, are used as a compatible droplet emulsifier that stabilizes droplets containing cells inside without harming or altering the cells. Fluorosurfactants are soluble in a fluorinated oil (continuous phase) but insoluble in the aqueous phase, which results in decreasing the aqueous-fluorous interfacial tension. For example, a triblock copolymer surfactant containing two perfluoropolyether (PFPE) tails and a polyethylene glycol (PEG) block head group is a fluorosurfactant with great biocompatibility and excellent droplet stability against coalescence. Another example are the fluorinated linear polyglycerols, which can be further functionalized on their tailored side-chains and are more customizable compared to the PEG-based copolymer. Surfactants can be purchased from many chemical companies, such as RainDance Technologies (now through BioRad) and Miller-Stephenson.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.